批量添加靶点（上传文件）
<p>[TOC]</p>
<h5>简要描述</h5>
<ul>
<li>批量添加靶点（上传文件）</li>
</ul>
<h5>请求URL</h5>
<ul>
<li><code>http://119.136.27.201:3200/targets/batch</code></li>
</ul>
<h5>请求方式</h5>
<ul>
<li>POST </li>
</ul>
<h5>参数</h5>
<table>
<thead>
<tr>
<th style="text-align: left;">参数名</th>
<th style="text-align: left;">必选</th>
<th style="text-align: left;">类型</th>
<th>说明</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align: left;">file</td>
<td style="text-align: left;">是</td>
<td style="text-align: left;">文件</td>
<td>上传的文件</td>
</tr>
</tbody>
</table>
<h5>返回示例</h5>
<pre><code>{
"data": {
"success": [{
"Type": "Reviewed",
"Gene symbol": "APOC3",
"Ensemble gene ID": "",
"Transcript ID": "",
"Gene function summary": "slows down the breakdown of fats",
"Disease name": "Familial chylomicronaemia syndrome (FCS) (also known as type I hyperlipoproteinaemia)",
"Phenotype": "The excess fat accumulates in organs such as the spleen and liver, which become abnormally enlarged.[5] Fat accumulation can also cause repeated bouts of pancreatitis (inflammation of the pancreas) and xanthomas (formation of yellow fatty deposits just under the skin, generally around joints)[5]",
"Population size": "1/1m",
"Etiology Organ": "Liver",
"Mechanism": "FCS is caused by insufficient or impaired function of the enzyme, lipoprotein lipase (LPL), which is responsible for breaking down (metabolizing) triglycerides.",
"Drug name": "VOLANESORSEN",
"Modality": "ASO",
"MOA": "RNA degradation",
"Company": "Ionis Pharmaceuticals",
"Clinical Stage": "Approved (EMA)",
"Safety": "The most common side effects were injection site reactions, flu-like symptoms, hypersensitivity, liver and renal side effects and thrombocytopenia.",
"Efficacy": "participants given volanesorsen had an average 77% reduction in the level of triglycerides compared with an average 18% increase in participants given placebo (a dummy treatment).",
"Drug Bank": "",
"ChEMBL": "",
"Drug Central": "",
"Genetic evidence": "",
"Rationale summary": "1. No need for injection",
"Category": "",
"Area": "Rare Disease",
"Status": "BLANK",
"owner": "Xing",
"Review": "",
"FDA sheet": ""
}],
"fail": [{
"Type": "Reviewed",
"Gene symbol": "TTR",
"Ensemble gene ID": "ENSG00000118271.12",
"Transcript ID": "ENST00000237014.8",
"Gene function summary": "This protein transports vitamin A (retinol) and a hormone called thyroxine throughout the body.",
"Disease name": "hereditary transthyretin-mediated amyloidosis",
"Phenotype": "pain,?paresthesia,?muscular weakness?and?autonomic dysfunction. In its terminal state, the?kidneys?and the?heart?are affected. FAP is characterized by the systemic deposition of?amyloidogenic?variants of the?transthyretin?protein, especially in the?peripheral nervous system, causing a progressive sensory and motor?polyneuropathy.",
"Population size": "worldwide prevalence at 50,000 individuals, with varying phenotypic presentations",
"Etiology Organ": "Multi-organ",
"Mechanism": "FAP is caused by a mutation of the TTR gene, located on human chromosome 18q12.1-11.2.[5] A replacement of valine by methionine at position 30 (TTR V30M) is the mutation most commonly found in FAP.[1] The transthyretin protein is a tetramer. The tetramer has to dissociate into misfolded monomers to aggregate into a variety of structures including amyloid fibrils. Because most patients are heterozygotes, they deposit both mutant and wild type TTR subnits.",
"Drug name": "PATISIRAN",
"Modality": "siRNA",
"MOA": "RNAI INHIBITOR",
"Company": "Alnylam Pharmaceuticals",
"Clinical Stage": "Approved ",
"Safety": "Flushing, chills, dizziness, shortness of breath, chest discomfort/pain, fast/pounding heartbeat, or facial swelling may occur during the injection. Back/neck/muscle/joint pain, nausea, abdominal pain, headache, or tiredness may also occur.",
"Efficacy": "",
"Drug Bank": "",
"ChEMBL": "",
"Drug Central": "",
"Genetic evidence": "",
"Rationale summary": "1. No need for injection \r\n2. better biodistribution with compound",
"Category": "",
"Area": "Rare Disease",
"Status": "BLANK",
"owner": "Sam",
"Review": "",
"FDA sheet": "",
"error": "invalid owner",
}]
},
"code": 200,
"message": "success"
}</code></pre>
<h5>返回参数说明</h5>
<table>
<thead>
<tr>
<th style="text-align: left;">参数名</th>
<th style="text-align: left;">类型</th>
<th>说明</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align: left;">success</td>
<td style="text-align: left;">list</td>
<td>上传成功的实验数据列表，实验字段描述参考 ”新建ShapeMap实验信息“ 接口</td>
</tr>
<tr>
<td style="text-align: left;">fail</td>
<td style="text-align: left;">list</td>
<td>上传失败的实验数据列表</td>
</tr>
<tr>
<td style="text-align: left;">error</td>
<td style="text-align: left;">list</td>
<td>上传失败原因</td>
</tr>
</tbody>
</table>
<h5>备注</h5>
<ul>
<li>上传文件前可先下载示例文件：targets_example_file.csv ，数据内容根据示例文件填写</li>
</ul>